Are These On Your List Of Penny Stocks to Watch Today?
Penny stocks have been some of the best performers this year. Thanks in part to the coronavirus, cheap stocks have gone on to become industry competitors. Whether it is from the testing side or the vaccine niche, biotech penny stocks have been a key focus for traders and investors alike. Just look at Applied DNA Sciences Inc. (APDN Stock Report).
This was one of the penny stocks we started to watch earlier this year, in January. At the time, Applied DNA was focusing entirely on its “DNA tag” to mark leather; yes, leather of all things. Then COVID-19 came about and the company shifted focus. Fast-forward to this week and that $4 penny stock has just broken above $13 during Monday’s premarket session.
[Special Report] Gold Stocks Back In Focus As Fed Prints More Cash
The company announced with its COVID-19 vaccine development partner Takis Biotech that the first injections of the DNA vaccine candidates against the Spike protein of the SARS-CoV-2 virus have produced neutralizing antibodies in test animals. The company said that, “These initial results were obtained using plasmids (the templates for LinearDNA™) to baseline results; Applied DNA’s linear DNA dose-response trials begin this week. “
This isn’t an outlier either. We’ve seen plenty of penny stocks under $4 and even penny stocks under $1 jump well-above the $5 threshold. Given this, it may be beneficial to look for some penny stocks to add to your list. Will they be the best penny stocks to buy today? You be the judge.
Penny Stocks To Buy [or sell]: Oragenics Inc.
Shares of Oragenics Inc. (OGEN Stock Report) have been in rally mode for the last few weeks. After gapping down in mid-April, the penny stock has steadily climbed. Last week, Friday saw OGEN stock trade some of its highest share volume since April 15th. Why did OGEN drop in the first place? The company reported topline results of a Phase 2 trials missed the endpoint. The trial was on the company’s AG013 to treat oral mucositis in chemoradiation in head and neck cancer patients.
Over the last few days, OGEN stock saw a strong reversal in the downtrend from April. While there wasn’t much news last week, this week kicks off with a big announcement. Oragenics announced its acquisition of Noachis Terra Inc. to develop and commercialize TerraCoV2, a vaccine candidate that could provide specific immunity from the novel coronavirus. According to the company, Noachis Terra Inc. holds a worldwide, nonexclusive license to the TerraCoV2 vaccine candidate from the National Institute of Allergy and Infectious Diseases. The biggest question is will today’s update be enough of a catalyst to maintain the recent uptrend that began last week?
“Our strategic acquisition of Noachis Terra marks a significant milestone in our history, as we are now prepared to advance the development of immunizations that target the devastating COVID-19 pandemic,” stated Alan Joslyn, Ph.D., president and CEO of Oragenics.
Penny Stocks To Buy [or sell]: IZEA Worldwide Inc.
IZEA Worldwide Inc. (IZEA Stock Report) has been another one of the more quiet penny stocks to watch. There hasn’t been much excitement this year except for a few standout days in April and late-May. Both of those “bigger days” ended up closing red. On Monday, IZEA stock gapped up at the opening bell and reach premarket highs of $0.37.
Why did IZEA stock jump today? The comapny announced a streaming event to demonstrate the latest capabilities of BrandGraph®, its newly released social intelligence platform. According to the company, BrandGraph provides analysis of share-of-voice, engagement benchmarking, category spending estimates, influencer identification, and sentiment analysis.
- What Is The Best App For Penny Stocks?
- Junior Gold Stocks Creating Massive Opportunity for Investors!
IZEA’s Founder and CEO, Ted Murphy will host the event on May 18th to discuss this platform and demonstrate key features. This news seems to have been enough to excite the market. IZEA stock also hit new 2020 highs of $0.386. The biggest question right now: will Monday see the same results as March 31 and April 17; the last two “big days” of activity in the penny stock?
Penny Stocks To Buy [or sell]: Akorn Inc.
One of the penny stocks to watch in April was Akorn Inc. (AKRX Stock Report). At the time, the penny stock traded around $0.20 and managed to run as high as $0.49 within a few days. But again, the company hasn’t really been making any major headlines that could justify the volatility. Case in point, look what the company’s CEO said in a PR this year:
“Unfortunately, our sale process has been negatively impacted by the broader market uncertainties related to the COVID-19 crisis. However, we are working closely with our lenders to determine the best path forward to ensure that the Company is positioned for long-term success.”Doug Boothe, Akorn’s President and Chief Executive Officer
What’s more is that in a recent industry update, Akorn was replaced on the S&P SmallCap 600. The index cited that “Akorn intends to file for reorganization under Chapter 11 of the U.S. Bankruptcy Code by May 1, 2020 and will no longer be eligible for continued inclusion in the S&P SmallCap 600.” But since the company is is engaged in the development, manufacturing, and marketing of generic and prescription pharmaceuticals, could there still be “something” in its pipeline to justify this type of interest? Without any new filings or news, the market for AKRX stock could be much more based on speculation than fundamentals. Where do you think AKRX will be by the end of May? Comment below.
Penny Stocks To Buy [or sell]: MicroVision
This was on the list of penny stocks from Friday. MicroVision (MVIS Stock Report) has continued much higher on May 4th. Ever since dropping to 52-week lows of $0.153 in March, MVIS stock has been on the move. Earlier in April we reported on MicroVision. At the time, the stock was trading around $0.21, not far off of where it started this week. Similar to this week, shares of Microvision climbed for no apparent reason.
A few weeks prior, the company announced that it would hand off the production of certain components the company was making. It would give the task to its “April 2017 customer”. The agreement still allows Microvision to profit from each component shipped via a royalty.
This week the company’s stock may be in the spotlight ahead of its earnings report. On May 7, MicroVision is slated to release its Q1 2020 results. What may be more important to note is that the company is “exploring strategic alternatives”. Earlier this month the company retained Craig-Hallum Capital Group LLC to serve as its financial advisor as it explores various licensing and other strategic alternatives. The company said this includes a potential sale or merger of the company.
As we’ve seen in the past with companies “exploring strategic alternatives,” speculation can play a big role in the market. For MVIS stock, shares have jumped over 420% since April 14th. Will these upcoming earnings reveal the next move for MicroVision or is this a “buy the rumor, sell the news” situation?